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SUMMARY
Osteoporosis is defined as a skeletal disorder characterized by compromised bone strength
predisposing to an increased risk of fracture. Men as well as women are affected by osteoporosis,
a disease that can be prevented and treated. In Japan, around１３milion people already have osteo-
porosis or are high risk due to low bone mass. Hip and spine fractures are linked with increased
mortality, and all fractures may lead to disability and reduced quality of life. Antiresorptive agents
for osteoporosis are a cornerstone of therapy, and anabolic drugs have recently increased our op-
tions. Treatment of osteoporosis most commonly involves lifestyle changes and medications and
aims to maximise bone density and reduce the risk of bone fracture.
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